<DOC>
	<DOCNO>NCT01119638</DOCNO>
	<brief_summary>Behavioral psychological symptom dementia ( BPSD ) among distress manifestation dementia . Pharmacotherapy frequently use especially institutional setting . Current guideline recommend use second-generation antipsychotic ( SGAs ) . Nonetheless , concern regard safety effectiveness patient dementia . Inconclusive evidence support use psychoactive agent SSRI antidepressant cognitive enhancer . In two published study citalopram efficacious , well tolerate perphenazine risperidone patient BPSD . Thus , proven efficacy beneficial safety profile evaluation use escitalopram BPSD warrant .</brief_summary>
	<brief_title>Escitalopram Treatment BPSD Alzheimer 's Disease Comparison Risperidone</brief_title>
	<detailed_description>Behavioral psychological symptom dementia ( BPSD ) agitation psychosis among distress manifestation dementia . The evidence-based management symptom include search treatable physical environmental precipitant , support psychoeducation primary caregiver psychosocial intervention . Nevertheless , pharmacotherapy frequently use especially institutional setting . Current guideline recommend use second-generation antipsychotic ( SGAs ) . Nonetheless , concern regard safety effectiveness patient dementia . Recent research result 'black-box '' warn concern safety use SGAs BPSD . Sparse inconclusive evidence support use psychoactive agent SSRI antidepressant cognitive enhancer . In two published randomize controlled trial , citalopram efficacious placebo efficacious , well tolerate perphenazine risperidone patient dementia hospitalize treatment agitation psychosis . Thus , proven efficacy beneficial safety profile evaluation use escitalopram BPSD warrant . A 6-week parallel group , randomize , control trial patient dementia hospitalize behavioral symptom conduct Abarbanel MHC . Participants consecutively recruit inpatient unit . Randomization base table random number hold centrally uninvolved physician . The study `` double-blind '' design . All medication identical packaging distribute ward central pharmacy .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Eligible participant fulfill criterion dementia Alzheimer 's type ( accord Diagnostic Statistical Manual Mental Disorders , fourth edition ) . The score MiniMental State Examination ( MMSE ) 5 26 . Eligible patient suffer delusion , hallucination , aggression , agitation develop onset dementia severe enough disrupt functioning , opinion study physician , justify treatment antipsychotic drug . Signs symptoms psychosis , aggression , agitation occur nearly daily week prior enrollment . A frequency rating `` often '' `` frequently '' severity rating least `` moderate '' require delusion , hallucination , agitation , `` aberrant motor behavior '' Neuropsychiatric Inventory ( NPI ) . Patients exclude received diagnosis primary psychotic disorder ( e.g. , schizophrenia ) , delirium , dementia . Patients also exclude go receive treatment cholinesterase inhibitor antidepressant medication , previously treat escitalopram BPSD , contraindication two study drug .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>BPSD</keyword>
	<keyword>escitalopram</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Agitation</keyword>
	<keyword>Psychosis</keyword>
	<keyword>Dementia</keyword>
	<keyword>Elderly</keyword>
</DOC>